Current treatment options in systemic sclerosis (Scleroderma)

Acta Medica Austriaca

Volumn 29, Issue 1, 2002, Pages 14-19

  Stummvoll, Georg H ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Systemic sclerosis (scleroderma); Treatment

Indexed keywords

AZATHIOPRINE; CHLORAMBUCIL; COLCHICINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUOROURACIL; GAMMA INTERFERON; IMMUNOMODULATING AGENT; METHOTREXATE; PENICILLAMINE;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; BLOOD TOXICITY; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE SEVERITY; ESOPHAGUS MOTILITY; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TRACT; HEART DISEASE; HEMODIALYSIS; HUMAN; IMMUNOPATHOGENESIS; INFLAMMATION; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; KIDNEY DISEASE; LUNG ALVEOLITIS; MUSCULOSKELETAL DISEASE; PATHOGENESIS; PLASMAPHERESIS; PULMONARY HYPERTENSION; PUVA; RAYNAUD PHENOMENON; REVIEW; SCLERODERMA; SKIN; SKIN MANIFESTATION; SMALL INTESTINE; STEM CELL TRANSPLANTATION; SYSTEMIC SCLEROSIS; T LYMPHOCYTE;

ANTIRHEUMATIC AGENTS; GASTROINTESTINAL DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; HYPERTENSION, PULMONARY; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; PENICILLAMINE; PHOTOTHERAPY; PLASMAPHERESIS; RAYNAUD DISEASE; SCLERODERMA, SYSTEMIC;

EID: 0036046403     PISSN: 03038173     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1563-2571.2002.01038.x     Document Type: Review

References (102)

1. Activation of dermal connective tissue in scleroderma
2. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma
3. Immunopathogenesis of systemic sclerosis
4. Role of T cells and cytokines in effecting fibrosis
5. Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations
6. Lymphocyte phenotyping in systemic sclerosis: A flow cytometry analysis of lymphocytes in bronchoalveolar lavage fluid
7. Fibrosing alveolitis in systemic sclerosis: Increase in memory T-cells in lung interstitium
8. Increase in activated T cells and reduction in suppressor inducer T cells in systemic sclerosis
9. Derangement of apoptosis-related lymphocyte homeostasis in systemic sclerosis
10. Soluble and cellular markers of immune activation in patients with systemic sclerosis
11. Cutting edge: Persistent fetal microchimerism in T lymphocytes is associated with HLA-DQAI*0501: Implications in autoimmunity
12. Microchimerism and the causation of scleroderma
13. Soluble interleukin-2 receptor, interleukin-2 and interleukin-4 in sera and supernatants from patients with progressive systemic sclerosis
14. Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma
15. Elevated serum levels of interleukin 4 (IL-4), IL-10, and Il-13 in patients with systemic sclerosis
16. Elevated serum tumor necrosis factor-alpha levels in patients with systemic sclerosis: Association with pulmonary fibrosis
17. Immunologic parameters in systemic sclerosis
18. Anti-TGF-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: A model for human scleroderma
19. Immunocytochemical localization and serologic detection of transforming growth factor beta 1. Association with type I procollagen and inflammatory cell markers in diffuse and limited systemic sclerosis, morphea, and Raynaud's phenomenon
20. Elevated levels of platelet derived growth factor and transforming growth factor-beta 1 in bronchoalveolar lavage fluid from patients with scleroderma
21. Elevated expression of beta 1 and beta 2 integrins, intercellular adhesion molecule 1, and endothelial leukocyte adhesion molecule 1 in the skin of patients with systemic sclerosis of recent onset
22. Endothelin-1 regulation of intercellular adhesion molecule-1 expression in normal and sclerodermal fibroblasts
23. Characterization of autoantibodies to endothelial cells in systemic sclerosis (SSc): Association with pulmonary fibrosis
24. Treatment of systemic sclerosis
25. Treatment of systemic sclerosis by disease modifying agents
26. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: High-dose versus low-dose penicillamine trial
27. D-Penicillamine therapy in progressive systemic sclerosis (scleroderma): A retrospective analysis
28. A 15-year prospective study of treatment of rapidly progressive systemic sclerosis with D-penicillamine
29. Penicillamine in systemic sclerosis: A reappraisal
30. D-penicillamine treatment in systemic sclerosis
31. Treatment of systemic sclerosis
32. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: Analysis of a two-year, double-blind, randomized, controlled clinical trial
33. In vitro inhibition of hematopoiesis in a patient with systemic sclerosis treated with D-penicillamine
34. Pemphigus vulgaris induced by D-penicillamine therapy in a patient with systemic sclerosis
35. D-penicillamine-induced crescentic glomerulonephritis and antimyeloperoxidase antibodies in a patient with scleroderma. Case report and review of the literature
36. Generalized scleroderma. Treatment with an immunosuppressive agent
37. Immunosuppression with chlorambucil, versus placebo, for scleroderma. Results of a three-year, parallel, randomized, double-blind study
38. Colchicine suppression of local inflammation due to calcinosis in dermatomyositis and progressive systemic sclerosis
39. Efficacy of cyclosporin A in systemic sclerosis
40. Cyclosporine in systemic sclerosis. Results of a forty-eight-week open safety study in ten patients
41. Cyclosporin A treatment of systemic sclerosis
42. Cyclosporin and tacrolimus: Their use in a routine clinical setting for scleroderma
43. Acute renal failure occurring in scleroderma treated with cyclosporin A: A report of three cases
44. 5-fluorouracil in the treatment of scleroderma: A randomised, double blind, placebo controlled international collaborative study
45. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis
46. Treatment of systemic sclerosis with recombinant interferon-gamma. A phase I/II clinical trial
47. Recombinant interferon-gamma in the treatment of systemic sclerosis
48. Interferon-gamma induced exacerbation of systemic lupus erythematosus
49. Induction of systemic lupus erythematosus by interferon-gamma in a patient with rheumatoid arthritis
50. Methotrexate treatment in scleroderma
51. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma
52. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis
53. Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide
54. Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma
55. Normotensive renal failure in systemic sclerosis
56. Scleroderma
57. Severe restrictive lung disease in systemic sclerosis
58. Parenteral administration of 8-methoxypsoralen in photopheresis
59. Clinical and mechanistic aspects of photopheresis
60. Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapy
61. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease
62. Treatment of systemic sclerosis with extracorporeal photochemotherapy. Results of a multicenter trial
63. Three cases of progressive systemic sclerosis treated with extracorporeal photochemotherapy
64. Management of severe scleroderma with long-term extracorporeal photopheresis
65. Extracorporeal photochemotherapy in progressive systemic sclerosis: A follow-up study
66. Photopheresis treatment enhances CD95 (fas) expression in circulating lymphocytes of patients with systemic sclerosis and induces apoptosis
67. Plasmapheresis and immunosuppressive drug therapy in scleroderma
68. Treatment of progressive systemic sclerosis with plasma exchange. Seven cases
69. Treatment of systemic sclerosis with autologous haemopoietic stem cell transplantation
70. Immune ablation and stem-cell therapy in autoimmune disease. Clinical experience
71. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: Procedure related mortality and impact on skin disease
72. The peripheral vascular effects of nifedipine in Raynaud's syndrome associated with scleroderma: A double blind crossover study
73. Losartan therapy for Raynaud's phenomenon and scleroderma: Clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial
74. Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis
75. Efficacy evaluation of prostaglandin E1 against placebo in patients with progressive systemic sclerosis and significant Raynaud's phenomenon
76. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: A double blind randomised study
77. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis
78. Ketanserin: An effective treatment regimen for digital ischaemia in systemic sclerosis
79. Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine
80. Adventitial stripping: A digit saving procedure in refractory Raynaud's phenomenon
81. Surgery in patients with systemic sclerosis of the hand
82. Treatment of oesophagitis in scleroderma with omeprazole
83. Gastrointestinal motility disorders in scleroderma
84. The effect of cisapride on gastro-oesophageal dysfunction in systemic sclerosis: A controlled manometric study
85. The risk of serious cardiac arrhythmias among cisapride users in the United Kingdom and Canada
86. Cisapride and fatal arrhythmia
87. Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma
88. Small bowel bacterial overgrowth in systemic sclerosis: Detection using direct and indirect methods and treatment outcome
89. Outcome of renal crisis in systemic sclerosis: Relation to availability of angiotensin converting enzyme (ACE) inhibitors
90. Cardiac involvement in systemic sclerosis
91. The effect of nifedipine on myocardial perfusion and metabolism in systemic sclerosis. A positron emission tomographic study
92. Epidemiology and natural history of systemic sclerosis
93. Mortality and causes of death in a Swedish series of systemic sclerosis patients
94. Serial pulmonary function in systemic sclerosis
95. Fibrosing alveolitis in systemic sclerosis. Bronchoalveolar lavage findings in relation to computed tomographic appearance
96. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin
97. Systemic sclerosis-associated pulmonary hypertension: Short- and long-term effects of epoprostenol (prostacyclin)
98. The acute effects of prostacyclin on pulmonary hemodynamics in patients with pulmonary hypertension secondary to systemic sclerosis
99. Lung transplantation for respiratory failure resulting from systemic disease
100. Single lung transplantation in patients with systemic disease
101. Lung transplantation in patients with scleroderma
102. Disease modifying therapy in scleroderma